MedTrace Logo

ERAS® Guidelines Validation of CRS With or Without HIPEC

NCT05185791 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 288

Last updated 2022-01-11

No results posted yet for this study

Summary

Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative care. Recently an international panel of expert have succeeded to elaborate dedicated recommendations for cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) in a two-part series of guidelines based on expert consensus (Hübner et al., EJSO, 2020). The aim of this prospective validation study was therefore to study acceptance, feasibility and clinical results of these guidelines in clinical practice.

Hypothesis of the study: Introduction of ERAS® guidelines is feasible and safe. Increasing compliance with ERAS® guidelines (after implementation) will improve recovery and early clinical outcomes of patients undergoing CRS/HIPEC.

Conditions

  • Peritoneal Diseases

Interventions

OTHER

Pre-ERAS® phase (current clinical practice)

Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.

OTHER

Post-ERAS® implementation phase

Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Olivier Glehen, MD, PhD · Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-06-30
Completion
2022-08-31

Countries

  • United States
  • Canada
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05185791 on ClinicalTrials.gov